KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables: 2018-2024

Historic Receivables for Adaptive Biotechnologies (ADPT) over the last 7 years, with Dec 2024 value amounting to $43.0 million.

  • Adaptive Biotechnologies' Receivables rose 9.99% to $46.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.0 million, marking a year-over-year increase of 11.80%. This contributed to the annual value of $43.0 million for FY2024, which is 10.42% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Receivables stood at $43.0 million for FY2024, which was up 10.42% from $39.0 million recorded in FY2023.
  • Adaptive Biotechnologies' Receivables' 5-year high stood at $43.0 million during FY2024, with a 5-year trough of $10.9 million in FY2020.
  • Over the past 3 years, Adaptive Biotechnologies' median Receivables value was $40.9 million (recorded in 2022), while the average stood at $41.0 million.
  • Its Receivables has fluctuated over the past 5 years, first decreased by 27.39% in 2020, then spiked by 117.22% in 2022.
  • Adaptive Biotechnologies' Receivables (Yearly) stood at $10.9 million in 2020, then skyrocketed by 71.82% to $18.8 million in 2021, then surged by 117.22% to $40.9 million in 2022, then decreased by 4.62% to $39.0 million in 2023, then climbed by 10.42% to $43.0 million in 2024.